CD40-CD40L相互作用在系统性自身免疫病中的研究进展
本文综述CD40-CD40L通路在系统性红斑狼疮、干燥综合征和类风湿关节炎等系统性自身免疫病中的核心作用,涵盖适应性免疫、固有免疫、组织炎症及血小板驱动的血栓炎症,并总结抗CD40/CD40L抗体的早期试验及Fc沉默抗体工程进展,支持该通路阻断作为基于机制的治疗策略。
要点
- CD40-CD40L是连接易感性与效应性疾病的核心通路,调控抗原提呈、T-B细胞协作和生发中心反应。
- 该通路还参与滤泡外自身抗体产生、固有免疫启动、组织炎症和血小板驱动的血栓炎症。
- Fc沉默抗体工程可保留靶点结合并减少血小板活化,支持CD40-CD40L阻断的临床转化。
核心结论
- CD40-CD40L阻断是系统性自身免疫风湿病中重新焕发前景的基于机制的治疗策略。
研究设计与样本
- 本文为综述,聚焦系统性红斑狼疮、干燥综合征和类风湿关节炎,总结CD40-CD40L通路的免疫学作用及治疗转化进展。
主要发现
- CD40-CD40L是抗原提呈、T-B细胞协作和生发中心反应的中心调节因子,并参与滤泡外自身抗体产生。
- 该通路在适应性免疫、固有免疫启动、组织炎症和血小板驱动的血栓炎症中发挥多方面作用。
- 抗CD40/CD40L抗体的早期试验及Fc沉默抗体工程进展支持该通路作为治疗靶点。
临床怎么用
- CD40-CD40L阻断可作为系统性红斑狼疮、干燥综合征和类风湿关节炎的基于机制的治疗策略。
- Fc沉默抗体工程可在保留靶点结合的同时减少血小板活化,支持抗CD40/CD40L抗体的临床开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic autoimmune diseases arise from a heterogeneous interplay of genetic, epigenetic, and environmental factors that culminates in loss of tolerance, chronic inflammation, and tissue injury. Among the pathways linking susceptibility to effector disease, CD40-CD40L is a central regulator of antigen presentation, T-B cell collaboration, and germinal centre responses, while also contributing to extrafollicular autoantibody production. In this review, we first introduce the disease-specific rationale for targeting CD40-CD40L interactions, with a particular focus on systemic lupus erythematosus, Sjögren's disease, and rheumatoid arthritis. We then summarize the multifaceted roles of CD40-CD40L signalling across adaptive immunity, innate immune priming, tissue inflammation, and platelet-driven thrombo-inflammation. Finally, we review the therapeutic translation of this pathway, highlighting insights from early trials of anti-CD40/CD40L antibodies and recent advances in Fc-silent antibody engineering that preserve target binding while minimizing platelet activation. Together, these data support CD40-CD40L blockade as a renewed and promising mechanism-based strategy in systemic autoimmune rheumatic diseases.
引用
- Hashimoto M, Katsushima M, Mackay F, et al. CD40-CD40L interactions in systemic autoimmune diseases. Rheumatology (Oxford). 2026. PMID: 42885554. doi:10.1093/rheumatology/keag565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。